FDA Approves Longer-Lasting Version of Lyrica for Diabetic, Shingles Pain

Pfizer has secured FDA approval for a longer-lasting version of its drug Lyrica.

The once-daily tablet Lyrica CR is cleared for treatment of shingle- or diabetic peripheral neuropathy-related pain, but does not share the original Lyrica formula’s indication for fibromyalgia. The approval comes in the wake of several generics manufacturers securing tentative approvals to develop their own copies of the drug.

Last year, Lyrica made Pfizer more than $13 billion in the U.S. alone.